25
2020-11
Female Subjects Included in Clinical Trial of Proxalutamide Treating COVID-19
Kintor Pharmaceutical Limited announced that the clinical trial of Proxalutamide in the treatment of COVID-19 was based on the positive results preliminarily shown in the treatment of male subjects.
25
2020-11
Kintor Pharmaceutical’s SMO Antagonist Obtains Approval of Clinical Trial from FDA
Kintor Pharmaceutical Limited announced that its SMO antagonist GT1708F was approved by the US Food and Drug Administration for clinical trials, and the treatment of basal cell carcinoma will be commenced.
24
2020-11
Kintor Pharmaceutical Limited announced that the Company’s Suzhou Industrialisation Base was granted the Pharmaceutical Production License issued by Jiangsu Medical Products Administration.
29
2020-10
Kintor Pharmaceutical's COVID-19 Clinical Trials for Proxalutamide to expand Patient Enrolment
Kintor Pharmaceutical Limited is delighted to announced that the clinical trial of anti-androgen treatment Proxalutamide for the novel coronavirus disease (COVID-19) has reached the initial target of 381 patients enrolment on 25 October 2020.
27
2020-10
Kintor Pharmaceutical has been successfully selected as the excellent case of the advanced enterprises in 2020 science and technology Innovation of the People.cn upon provision of comments and recommendations by experts.
16
2020-10
On 16 October 2020, Kintor Pharmaceutical Limited (Stock code: 9939, “Kintor Pharmaceutical”) announced that it has entered into a strategic cooperation agreement on biological drug development with Pumis Pharmaceutical Co., Ltd (“Pumis”).
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn